Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma
Disease control
Recruiting now
This early-phase trial is testing a CAR-T cell therapy made using an automated process for people with relapsed or refractory large B-cell lymphoma. The study will enroll 12 adults whose cancer has not responded to or returned after first-line treatment. Researchers will measure …
Phase: EARLY_PHASE1 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC